SCHEMBL20596259

SCHEMBL20596259

COc1ccc(-n2ccc(=O)c3cc(F)c(F)cc32)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.37
▸ EGFR P00533 1/20 0.37
▸ MAOA P21397 1/20 0.37
▸ KDM4E B2RXH2 4/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ GRM1 Q13255 2/20 0.36
▸ TP53 P04637 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ GAA P10253 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KCNJ5 P48544 1/20 0.35
▸ KCNJ3 P48549 1/20 0.35
▸ GPR35 Q9HC97 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595817 0.85 KDM4E (0.42) KDM4EALDH1A1NPSR1MAPTRAB9A
SCHEMBL20596195 0.81 TAS1R3 (0.32) EGFRKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL20595982 0.76 MARS2 (0.47) EGFRALDH1A1HPGD
SCHEMBL30145274 0.76 MARS2 (0.47) EGFRALDH1A1HPGD
SCHEMBL20596021 0.75 LMNA (0.41) SMN1; SMN2TP53MAPTLMNA
SCHEMBL23121351 0.71 ATM (0.41) EGFRKDM4EALDH1A1HPGDMAPT
SCHEMBL31057944 0.69 CRHR1 (0.41) ALDH1A1GAAMAPTHSD17B10LMNA
SCHEMBL26676116 0.67 ALDH1A1 (0.48) MAOBMAOAKDM4EALDH1A1HPGD
SCHEMBL14291380 0.66 ROCK1 (0.51) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL1042563 0.65 MAPT (0.56) EGFRALDH1A1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MAOB 1615/4885EGFR 4095/4885MAOA 1919/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MAOB 1220/4885EGFR 3708/4885MAOA 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback